Compare LSTA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | CELU |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.3M |
| IPO Year | 2000 | 2019 |
| Metric | LSTA | CELU |
|---|---|---|
| Price | $1.00 | $1.00 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.9K | ★ 114.6K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $35,283,868.00 | $26,550,000.00 |
| Revenue This Year | N/A | $165.42 |
| Revenue Next Year | N/A | $305.36 |
| P/E Ratio | ★ N/A | $26.13 |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.96 | $0.56 |
| 52 Week High | $5.07 | $2.55 |
| Indicator | LSTA | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 35.76 |
| Support Level | $0.99 | $0.63 |
| Resistance Level | $1.28 | $1.43 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 11.02 | 5.73 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.